Highlights From the American Diabetes Association Scientific Session 2023
Listen now
Description
Data on a new crop of hormone analogues for weight loss—including an oral version of semaglutide and the triple agent retatrutide—were recently presented at the American Diabetes Association’s annual Scientific Sessions. Robert Gabbay, MD, PhD, the ADA’s chief scientific and medical officer, speaks with JAMA’s Jennifer Abbasi about this and other clinical data presented at the meeting.
Related Content:
New Weight Loss Drugs Make Headlines at Diabetes Meeting
More Episodes
What hard lessons did the US Department of Veterans Affairs (VA) learn in 3 decades of EHR development, and what can it teach us about building better AI in medicine? Stephen Fihn, MD, MPH, of the University of Washington, and formerly a leader in the VA’s EHR efforts, joins JAMA+ AI Editor in...
Published 10/08/24
Published 10/08/24
European Society of Cardiology Vice President Carlos Aguiar, MD, discusses clinical research highlights from the largest scientific meeting in cardiovascular medicine, held recently in London. Updates include semaglutide findings, hypertension triple pills, and more.
Related Content:
...
Published 10/04/24
Links
Genres
Artwork or description wrong?
Request an update »
Updates may take a few minutes.
Do you host a podcast?
Track your ranks and reviews from Spotify, Apple Podcasts and more.
